5RKX | pdb_00005rkx

PanDDA analysis group deposition -- Crystal Structure of PHIP in complex with Z1324080698


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 1.24 Å
  • R-Value Free: 
    0.211 (Depositor), 0.200 (DCC) 
  • R-Value Work: 
    0.192 (Depositor), 0.180 (DCC) 
  • R-Value Observed: 
    0.193 (Depositor) 

wwPDB Validation   3D Report Full Report


Ligand Structure Quality Assessment 


This is version 1.2 of the entry. See complete history


Literature

SAMPL7 protein-ligand challenge: A community-wide evaluation of computational methods against fragment screening and pose-prediction.

Grosjean, H.Isik, M.Aimon, A.Mobley, D.Chodera, J.von Delft, F.Biggin, P.C.

(2022) J Comput Aided Mol Des 36: 291-311

  • DOI: https://doi.org/10.1007/s10822-022-00452-7
  • Primary Citation of Related Structures:  
    5RJJ, 5RJK, 5RJL, 5RJM, 5RJN, 5RJO, 5RJP, 5RJQ, 5RJR, 5RJS, 5RJT, 5RJU, 5RJV, 5RJW, 5RJX, 5RJY, 5RJZ, 5RK0, 5RK1, 5RK2, 5RK3, 5RK4, 5RK5, 5RK6, 5RK7, 5RK8, 5RK9, 5RKA, 5RKB, 5RKC, 5RKD, 5RKE, 5RKF, 5RKG, 5RKH, 5RKI, 5RKJ, 5RKK, 5RKL, 5RKM, 5RKN, 5RKO, 5RKP, 5RKQ, 5RKR, 5RKS, 5RKT, 5RKU, 5RKV, 5RKW

  • PubMed Abstract: 

    A novel crystallographic fragment screening data set was generated and used in the SAMPL7 challenge for protein-ligands. The SAMPL challenges prospectively assess the predictive power of methods involved in computer-aided drug design. Application of various methods to fragment molecules are now widely used in the search for new drugs. However, there is little in the way of systematic validation specifically for fragment-based approaches. We have performed a large crystallographic high-throughput fragment screen against the therapeutically relevant second bromodomain of the Pleckstrin-homology domain interacting protein (PHIP2) that revealed 52 different fragments bound across 4 distinct sites, 47 of which were bound to the pharmacologically relevant acetylated lysine (Kac) binding site. These data were used to assess computational screening, binding pose prediction and follow-up enumeration. All submissions performed randomly for screening. Pose prediction success rates (defined as less than 2 Å root mean squared deviation against heavy atom crystal positions) ranged between 0 and 25% and only a very few follow-up compounds were deemed viable candidates from a medicinal-chemistry perspective based on a common molecular descriptors analysis. The tight deadlines imposed during the challenge led to a small number of submissions suggesting that the accuracy of rapidly responsive workflows remains limited. In addition, the application of these methods to reproduce crystallographic fragment data still appears to be very challenging. The results show that there is room for improvement in the development of computational tools particularly when applied to fragment-based drug design.


  • Organizational Affiliation
    • Structural Bioinformatics and Computational Biochemistry, Department of Biochemistry, South Parks Road, OX1 3QU, Oxford, UK.

Macromolecules
Find similar proteins by:  (by identity cutoff)  |  3D Structure
Entity ID: 1
MoleculeChains Sequence LengthOrganismDetailsImage
PH-interacting protein149Homo sapiensMutation(s): 0 
Gene Names: PHIPDCAF14WDR11
UniProt & NIH Common Fund Data Resources
Find proteins for Q8WWQ0 (Homo sapiens)
Explore Q8WWQ0 
Go to UniProtKB:  Q8WWQ0
PHAROS:  Q8WWQ0
GTEx:  ENSG00000146247 
Entity Groups  
Sequence Clusters30% Identity50% Identity70% Identity90% Identity95% Identity100% Identity
UniProt GroupQ8WWQ0
Sequence Annotations
Expand
  • Reference Sequence
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 1.24 Å
  • R-Value Free:  0.211 (Depositor), 0.200 (DCC) 
  • R-Value Work:  0.192 (Depositor), 0.180 (DCC) 
  • R-Value Observed: 0.193 (Depositor) 
Space Group: C 1 2 1
Unit Cell:
Length ( Å )Angle ( ˚ )
a = 81.52α = 90
b = 27.47β = 100.11
c = 56.08γ = 90
Software Package:
Software NamePurpose
BUSTERrefinement
Aimlessdata scaling
PDB_EXTRACTdata extraction
XDSdata reduction
REFMACphasing

Structure Validation

View Full Validation Report



Ligand Structure Quality Assessment 


Entry History 

Revision History  (Full details and data files)

  • Version 1.0: 2020-06-17
    Type: Initial release
  • Version 1.1: 2024-03-06
    Changes: Data collection, Database references
  • Version 1.2: 2026-01-21
    Changes: Database references, Structure summary